Company
(Symbol)#*

Date filed

Shares/Units (M)

Price

Shares out

Lead, other underwriters

Gross (US$M)


Accelerated Pharma Inc. (Westport, Conn.; ACCP)1

10/13/16

1.67S

$5-$7

6.67

Rodman & Renshaw; Maxim Group

$10.02

Adienne Pharma & Biotech SA (Lugano, Switzerland; Swiss Stock Exchange)

9/15/16

N/A

N/A

N/A

N/A

N/A

Beyondspring Pharmaceuticals Inc. (New York; BYSI)2

11/21/16

N/A

N/A

N/A

Citigroup; China Renaissance

$100

Biolight Life Sciences Ltd. (Tel Aviv, Israel; BOLT)3

2/10/16

1.848S and W for 1.848S

N/A

4.45

Feltl and Co.; Rodman & Renshaw

$10

Braeburn Pharmaceuticals Inc. (Princeton, N.J.; BBRX)4

12/30/16

7.7S

$18-$21

N/A

J.P. Morgan; BofA Merrill Lynch; Deutsche Bank Securities; Canaccord Genuity

$150

Collplant Holdings Ltd. (Ness Ziona, Israel; CLGN)5

10/25/16

ADS

N/A

N/A

Ladenburg Thalmann; Roth Capital Partners

N/A

Gan & Lee Pharmaceuticals Ltd. (China)6

6/15/16

N/A

N/A

N/A

N/A

$227

Immuron Ltd. (Melbourne, Australia; IMROY)7

12/23/16

ADS

N/A

N/A

Joseph Gunnar

$18.3

Lysogene SA (Neuilly-sur-Seine, France; Euronext Paris:LYS)8

1/26/17

N/A

€6.80-€9.20

N/A

N/A

€39.7 (US$42.7)

Mapi-Pharma Ltd. (Ness Ziona; MAPI)

1/26/16

3.125S

$15-$17

11.76

JMP Securities; FBR; Maxim Group

$50

Therapix Biosciences (Tel-Aviv, Israel; TPRX)9

11/8/16

ADS

N/A

N/A

Rodman & Renshaw

$12

Verona Pharma plc (Cardiff, U.K.; LSE:VRP)10

11/28/16

N/A

N/A

N/A

N/A

N/A

Visterra Inc. (Cambridge, Mass.; VIST)

1/5/16

N/A

N/A

N/A

Leerink Partners; Stifel; Needham & Co.; Wedbush Pacgrow

$69

Viventia Bio Inc. (Winnipeg, Manitoba; VITA)

10/21/15

N/A

N/A

N/A

Leerink Partners; Cowen and Co.; Guggenheim Securities

$86.25


Notes

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

N/A = Not available, applicable or reported.

The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing.

This chart includes only biotech companies that develop therapeutics.

1 Accelerated's overallotment option: 250,000 shares.

2 Beyondspring filed an F-1 with the SEC seeking to raise up to $100M, including overallotments, in an IPO.

3 Biolight applied to list its shares for the first time in the U.S., although it already trades on the Tel Aviv Stock Exchange under the symbol "BOLT."

4 Braeburn's overallotment option: 1.15M shares. Apple Tree Partners was purchasing $50M in shares in the IPO and another $40M in a separate private placement.

5 Collplant is conducting its IPO in the U.S. by offering American Depositary Shares. It currently trades on the Tel Aviv Stock Exchange under the symbol "CLPT" and the ADSs are currently quoted on the OTCQX under "CQPTY". Each ADS represents 100 shares.

6 Gan & Lee plans to raise nearly ¥1.5B (US$227B) in an IPO in China

7 Immuron filed a registration statement on form F-1 relating to a proposed $18.3M IPO of its ADSs.

8 Lysogene's overallotment option: 646,875 shares.

9 Therapix filed form F-1 to raise $12M in an IPO through American depositary shares.

10 Verona Pharma is listed on AIM of the London Stock Exchange under the symbol VRP, but is seeking an IPO in the U.S.